Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:KLRS NASDAQ:KYTX NASDAQ:OCGN NASDAQ:OVID On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKLRSKalaris Therapeutics$3.98-1.6%$4.61$2.14▼$11.88$95.10M0.19623,596 shs395,149 shsKYTXKyverna Therapeutics$7.480.0%$8.44$2.80▼$13.67$458.39M1.87952,179 shs20,152 shsOCGNOcugen$1.31+0.4%$1.37$0.93▼$2.73$438.39M2.187.62 million shs24,376 shsOVIDOvid Therapeutics$2.39-1.0%$2.49$0.47▼$3.11$446.07M0.182.59 million shs413 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKLRSKalaris Therapeutics+1.00%-11.21%-14.41%-36.18%+66.94%KYTXKyverna Therapeutics+3.31%-5.79%-7.31%-26.88%+93.28%OCGNOcugen-2.26%-9.09%+4.84%-22.62%+28.71%OVIDOvid Therapeutics+4.33%-2.03%+6.17%-9.40%+298.08%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKLRSKalaris Therapeutics$3.98-1.6%$4.61$2.14▼$11.88$95.10M0.19623,596 shs395,149 shsKYTXKyverna Therapeutics$7.480.0%$8.44$2.80▼$13.67$458.39M1.87952,179 shs20,152 shsOCGNOcugen$1.31+0.4%$1.37$0.93▼$2.73$438.39M2.187.62 million shs24,376 shsOVIDOvid Therapeutics$2.39-1.0%$2.49$0.47▼$3.11$446.07M0.182.59 million shs413 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKLRSKalaris Therapeutics+1.00%-11.21%-14.41%-36.18%+66.94%KYTXKyverna Therapeutics+3.31%-5.79%-7.31%-26.88%+93.28%OCGNOcugen-2.26%-9.09%+4.84%-22.62%+28.71%OVIDOvid Therapeutics+4.33%-2.03%+6.17%-9.40%+298.08%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceKLRSKalaris Therapeutics 2.78Moderate Buy$15.60292.35% UpsideKYTXKyverna Therapeutics 2.67Moderate Buy$30.00301.23% UpsideOCGNOcugen 2.60Moderate Buy$9.50627.97% UpsideOVIDOvid Therapeutics 2.89Moderate Buy$5.13114.88% UpsideCurrent Analyst Ratings BreakdownLatest KLRS, OCGN, KYTX, and OVID Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/21/2026OVIDOvid Therapeutics B. Riley FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy7/17/2026OVIDOvid Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/7/2026KLRSKalaris Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/24/2026KYTXKyverna Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/23/2026KLRSKalaris Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/23/2026OCGNOcugen Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/15/2026KLRSKalaris Therapeutics TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy6/9/2026KLRSKalaris Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/3/2026KYTXKyverna Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.006/2/2026OCGNOcugen Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/27/2026OCGNOcugen Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$12.00 ➝ $11.00(Data available from 7/22/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookKLRSKalaris TherapeuticsN/AN/AN/AN/A$4.21 per shareN/AKYTXKyverna TherapeuticsN/AN/AN/AN/A$3.85 per shareN/AOCGNOcugen$4.47M98.94N/AN/A($0.04) per share-32.63OVIDOvid Therapeutics$7.25M61.40N/AN/A$1.00 per share2.39Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateKLRSKalaris Therapeutics-$43.44M-$2.15N/AN/AN/AN/A-72.78%-43.49%N/AKYTXKyverna Therapeutics-$161.31M-$3.28N/AN/AN/AN/A-81.88%-64.87%8/11/2026 (Estimated)OCGNOcugen-$67.85M-$0.24N/AN/AN/AN/A-127,987.80%-135.48%7/30/2026 (Estimated)OVIDOvid Therapeutics-$17.41M-$0.29N/AN/AN/A-240.11%-22.51%-18.67%8/12/2026 (Estimated)Latest KLRS, OCGN, KYTX, and OVID EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2026Q2 2026OVIDOvid Therapeutics-$0.10N/AN/AN/A$0.04 millionN/A8/11/2026Q2 2026KYTXKyverna Therapeutics-$0.67N/AN/AN/AN/AN/A7/30/2026Q2 2026OCGNOcugen-$0.05N/AN/AN/A$0.98 millionN/A5/12/2026Q1 2026KLRSKalaris Therapeutics-$0.52-$0.46+$0.06-$0.46N/AN/A5/12/2026Q1 2026KYTXKyverna Therapeutics-$0.75-$0.66+$0.09-$0.66N/AN/A5/12/2026Q1 2026OVIDOvid Therapeutics-$0.12-$0.12N/A-$0.12$0.06 millionN/A5/5/2026Q1 2026OCGNOcugen-$0.05-$0.06-$0.01-$0.06$0.42 million$1.53 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthKLRSKalaris TherapeuticsN/AN/AN/AN/AN/AKYTXKyverna TherapeuticsN/AN/AN/AN/AN/AOCGNOcugenN/AN/AN/AN/AN/AOVIDOvid TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioKLRSKalaris TherapeuticsN/A12.1912.19KYTXKyverna Therapeutics0.138.158.15OCGNOcugen4.171.861.86OVIDOvid Therapeutics0.0610.1710.17Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipKLRSKalaris Therapeutics66.05%KYTXKyverna Therapeutics18.08%OCGNOcugen10.27%OVIDOvid Therapeutics72.24%Insider OwnershipCompanyInsider OwnershipKLRSKalaris Therapeutics68.10%KYTXKyverna Therapeutics17.60%OCGNOcugen3.95%OVIDOvid Therapeutics7.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableKLRSKalaris Therapeutics11023.79 million7.59 millionN/AKYTXKyverna Therapeutics9660.80 million50.10 millionOptionableOCGNOcugen80338.52 million325.15 millionOptionableOVIDOvid Therapeutics60186.64 million173.58 millionOptionableKLRS, OCGN, KYTX, and OVID HeadlinesRecent News About These CompaniesOvid Therapeutics (NASDAQ:OVID) Short Interest UpdateJuly 17, 2026 | americanbankingnews.comOvid Therapeutics (NASDAQ:OVID) Sees Large Increase in Short InterestJuly 17, 2026 | marketbeat.comOvid Therapeutics (OVID) Appoints Kevin Norrett as Chief Business OfficerJuly 14, 2026 | insidermonkey.comOvid Therapeutics Boosts Capital Through Warrant ExercisesJuly 9, 2026 | theglobeandmail.comOvid Therapeutics Promotes Charles Carter to Chief Financial Officer in Leadership ShuffleJuly 8, 2026 | marketwatch.comOvid Therapeutics appoints Charles Carter as new CFOJuly 8, 2026 | tipranks.comOvid Therapeutics Strengthens Executive Leadership Team to Support Continued Pipeline Progress and Next Phase of DevelopmentJuly 8, 2026 | globenewswire.comOvid Therapeutics: Risk-Adjusted Valuation Shows Deep Discount Despite 700% RallyJuly 7, 2026 | seekingalpha.comOvid Therapeutics: Buy Next-Gen GABA-Aminotransferase Inhibitor OV329 And TSC/IS ExpansionsJuly 7, 2026 | seekingalpha.comOvid Therapeutics: Buy Next-Gen GABA-Aminotransferase Inhibitor OV329 And TSC/IS ExpansionsJuly 7, 2026 | seekingalpha.comAnalysts Offer Insights on Healthcare Companies: Voyager Therapeutics (VYGR), Ovid Therapeutics (OVID) and Establishment Labs Holdings (ESTA)June 9, 2026 | theglobeandmail.comOvid Therapeutics to Participate in Upcoming Investor ConferencesJune 4, 2026 | globenewswire.comOvid Therapeutics Expands Board, Appoints New Scientific DirectorJune 3, 2026 | tipranks.comOvid Therapeutics Appoints Leading Physician-Scientist and Biotech Innovator Anna Greka, M.D., Ph.D., to Board of DirectorsJune 3, 2026 | globenewswire.comOvid Therapeutics: Advancing Seizure Pipeline and Neuropsychiatric Programs Support Buy Rating and Unchanged $4 Price TargetMay 26, 2026 | tipranks.comFormer Ovid CEO Dr. Jeremy Levin’s rallying cry for biotechMay 15, 2026 | finance.yahoo.comWe're Hopeful That Ovid Therapeutics (NASDAQ:OVID) Will Use Its Cash WiselyMay 14, 2026 | finance.yahoo.comOvid Therapeutics Reports Business Updates and First Quarter 2026 Financial ResultsMay 12, 2026 | globenewswire.comHere is Why Ovid Therapeutics (OVID) is One of the Best Fast Growing Penny StocksMay 9, 2026 | insidermonkey.com5 Best Fast Growing Penny Stocks to Buy Right NowMay 8, 2026 | insidermonkey.comOvid Therapeutics Inc.April 20, 2026 | edition.cnn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeKLRS, OCGN, KYTX, and OVID Company DescriptionsKalaris Therapeutics NASDAQ:KLRS$3.98 -0.06 (-1.58%) As of 09:38 AM Eastern This is a fair market value price provided by Massive. Learn more.Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts.Kyverna Therapeutics NASDAQ:KYTX$7.48 0.00 (-0.04%) As of 09:38 AM Eastern This is a fair market value price provided by Massive. Learn more.Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.Ocugen NASDAQ:OCGN$1.30 +0.01 (+0.38%) As of 09:38 AM Eastern This is a fair market value price provided by Massive. Learn more.Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.Ovid Therapeutics NASDAQ:OVID$2.38 -0.03 (-1.04%) As of 09:38 AM Eastern This is a fair market value price provided by Massive. Learn more.Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Archer and Anduril Put ACHR Stock on a New Defense Flight Path 3M's Redemption Arc: Can Q2 Earnings Change the Narrative? Alphabet Is Planning a New AI Chip. Here's Why It Matters Ahead of Earnings Has Wall Street Got Monday.com Completely Wrong? 3 Photonics Companies Making Quantum Tech Possible Confidence Is Back, But Earnings Show the Consumer Is Being Picky Industrial and Utility Giants Boost Dividends as Data Center Tailwinds Build PayPal Rejected a $53 Billion Takeover Bid: Is the Stock Undervalued? Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
